Preferred Label : Lorukafusp alfa;
NCIt synonyms : Hu14.18-IL2; Hu14.18-IL2 Fusion Protein EMD 273063; Hu 14.18/IL - 2 Fusion Protein;
NCIt related terms : hu14.18-interleukin-2 fusion protein;
NCIt definition : A recombinant fusion protein comprised of hu14.18, a humanized immunoglobulin G1 (IgG1)
chimeric monoclonal antibody directed against the surface disialoganglioside GD2,
fused to two human pro-inflammatory cytokine interleukin (IL)-2 molecules, with potential
antineoplastic and immunomodulatory activities. Upon intravenous administration, the
antibody moiety of lorukafusp alfa specifically targets and binds to GD2 expressed
on certain tumor cells. This may stimulate the activation of immune effector cells
including natural killer (NK) and T-cells, leading to tumor cell death via antibody-dependent
cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and GD2-specifc
T-cell responses. By delivering IL-2 directly to the tumor microenvironment (TME),
IL-2 is able to further stimulate NK and T-cell antitumor cellular immune responses
locally. The glycosphingolipid GD2 is a tumor-associated antigen (TAA) overexpressed
on the surface of many tumor cells.;
Alternative definition : NCI-GLOSS: An anticancer drug in which hu14.18, a monoclonal antibody, is combined
with interleukin-2. The monoclonal antibody binds to the cancer cells and delivers
IL-2, which stimulates the immune system to destroy the cancer cells.;
UNII : PL21OR4LXE;
CAS number : 2131168-99-3;
Molecule name : APN 301; APN-301; EMD 273063; EMD-273063;
NCI Metathesaurus CUI : CL971111;
NSC code : 721298;
Codes from synonyms : CDR0000046190;
Origin ID : C162537;
UMLS CUI : C5139716;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_affects_cell_type_or_tissue
- chemical_or_drug_has_mechanism_of_action
- chemical_or_drug_has_physiologic_effect
- concept_is_in_subset
- has_target
